The national human papillomavirus (HPV) vaccination programme for men who have sex with men (MSM) began on 1 April 2018 and is being introduced via a phased roll out in all sexual health and human immunodeficiency virus clinics across England. As this programme can span up to two years, and some HPV-related diseases (i.e. cancers) take years to develop following infection, the full impact of this vaccination programme on the incidence of diseases will not be fully seen for many years. However, data is being collected to monitor the impact on diagnoses of anogenital warts and on the prevalence of HPV infection in MSM. It is expected that this will provide the earliest assessment of the initial effects of the programme in 2019/20.